Jambunathan R, Basavanna D, Vani P, Neuss M, Janbandhu P. One-year outcomes of a NeoHexa sirolimus-eluting coronary stent system with a biodegradable polymer in all-comers coronary artery disease patients: Results from NeoRegistry in India. World J Cardiol 2019; 11(8): 200-208 [PMID: 31523398 DOI: 10.4330/wjc.v11.i8.200]
Corresponding Author of This Article
Prashant Janbandhu, MSc, Medical Division, Sahajanand Laser Technology Ltd., Gandhinagar, Gujarat 382027, India. clinical@sltl.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. Aug 26, 2019; 11(8): 200-208 Published online Aug 26, 2019. doi: 10.4330/wjc.v11.i8.200
Table 1 Demographic and baseline clinical characteristics
Characteristics
n = 129 patients
Patient demographics
Age, yr
56.57 ± 11.73
Male
99 (76.74)
Baseline medical history
Diabetes mellitus
51 (39.53)
Hypertension
64 (49.61)
Smoking
11 (8.53)
Family history of coronary artery disease
04 (3.10)
History of alcohol consumption
05 (3.88)
Renal disease
01 (0.77)
Atrial fibrillation
01 (0.77)
Cardiac status - Angina class
I
08 (6.20)
II
26 (20.15)
III
71 (55.04)
IV
23 (17.83)
Unknown
01 (0.77)
Table 2 Lesion and procedural characteristics (n = 129 patients and 172 lesions)
Characteristics
n = 172 lesions
Target vessel location
LAD
73 (42.44)
LCx
37 (21.51)
RCA
56 (32.56)
Ramus
03 (1.74)
Other
03 (1.74)
Target lesion location
Ostial
05 (2.91)
Proximal
83 (48.26)
Mid
54 (31.39)
Distal
22 (12.79)
Unknown
08 (4.65%)
Lesion length
< 20 mm
39 (22.67)
20–40 mm
124 (72.09)
> 40 mm
08 (4.65)
Stenosis
88.12
Bifurcation
3 (1.74)
Thrombotic lesions
16 (9.30)
ACC/AHA lesion type
A
09 (5.23)
B
92 (53.49)
C
71 (41.28)
TIMI flow grade at baseline
0
45 (26.16)
1
49 (28.49)
2
72 (41.86)
3
05 (2.91)
Unknown
01 (0.58)
Average stent length
27.30 ± 9.20
Average stent diameter
2.98 ± 0.69
Average stent per patient
1.34 ± 0.53
Predilation
168 (97.67)
Postdilation
45 (26.16)
Table 3 Mortality, morbidity, and major adverse cardiac event, n (%)
Events
In-hospital
1 mo
6 mo
1 yr
MACE
0
01 (0.78)
05 (3.94)
06 (4.87)
Death
0
01 (0.78)
03 (2.36)
03 (2.44)
Myocardial infarction
0
0
01 (0.79)
01 (0.81)
Clinically driven TLR
0
0
01 (0.79)
02 (1.63)
Table 4 Stent thrombosis, n (%)
Timing of stent thrombosis
Incidence
Type of stent thrombosis
Incidence
Early
0
Definite
0
Late
01 (0.78)
Probable
02 (1.55)
01 (0.78)
Possible
Citation: Jambunathan R, Basavanna D, Vani P, Neuss M, Janbandhu P. One-year outcomes of a NeoHexa sirolimus-eluting coronary stent system with a biodegradable polymer in all-comers coronary artery disease patients: Results from NeoRegistry in India. World J Cardiol 2019; 11(8): 200-208